Prima BioMed to Present at 13th Annual Needham Healthcare Conference


SYDNEY, AUSTRALIA--(Marketwired - Apr 6, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company") today announced that its Chief Executive Officer, Matthew Lehman, will present at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 2:20 p.m. U.S. Eastern time (corresponds to Thursday, April 10 at 4:20 a.m. in Sydney) in New York City. Mr. Lehman will provide a Company overview and update on recent activities.

A live webcast of the presentation can be accessed via Prima's website at www.primabiomed.com.au or via the conference webcast service website at http://wsw.com/webcast/needham65/PBMD/. A replay will be available approximately one hour after the presentation.

About Prima BioMed
Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell- based product currently in clinical trials. www.primabiomed.com.au

Contact Information:

For further information please contact:

USA Investor/Media:
Adam Holdsworth
ProActive Capital
+1 (646) 862 4607


Australia Investor/Media:
Mr Matthew Gregorowski
Citadel Communications
+61 (0) 422 534 755


Europe Investor/Media:
Mr. Axel Mühlhaus
edicto GmbH
+49 (0) 69 905505-52


Prima BioMed Ltd
Level 7, 151 Macquarie Street
Sydney NSW 2000
Phone: +61 2 9276 1224
Fax: +61 2 9276 1284
www.primabiomed.com.au
ABN: 90 009 237 889